Cadila Healthcare Ltd

History:
Cadila Healthcare Ltd is a well known research-oriented, technology-driven
pharmaceutical company focused on the research areas of biotechnology, formulations
and Active Pharmaceutical Ingredients. They are an Indian based pharmaceutical
company having their presence around the world. They are having their manufacturing
facilities at Ahmedabad, Ankleshwar and Vadodara in Gujarat, Ponda in Goa, Raigad in
Maharashtra and Solan in Himachal Pradesh.

Cadila Healthcare Ltd, the flagship of Zydus Cadila Group was incorporated in May 1995
and they became a public limited company in July 1996. The company's operation
includes pharmaceuticals, which includes human formulations, veterinary formulations
and bulkdurgs, diagnostics, herbal products, skin care products and OTC products.

In the year 1996, the company made a strategic alliance with Gulin Pharma of China and
launched Falcigo in India, which is an anti-malarial segment. In May 2000, the company
acquired formulation business of Recon Ltd, which strengthens the company in the
southern market. In the year 2001, they acquired German Remedies which was the largest
M&A in the Indian Pharmaceutical sector and in the same year, they entered into a joint
venture with US based Onconova for collaborative research in the field of
Oncogenomics.

In April 2002, the company acquired Banyan Chemicals, a Vadodara based company
with the US FDA approved plant. In the year 2003, German Remedies, Recon
Healthcare, Zoom Properties and Zydus Pathline merged with the company. Also, they
acquired Alpharma France, which spearheaded the group operations in France. In the
same year, the company emerged as a 'Partner of Choice' for Schering AG to manufacture
and market the products in India.

In November 2004, the company entered into a strategic alliance with Zambon Group in
Italy to open up new avenues in contract manufacturing. In the same year, the company
entered into a long term strategic pact with Boehringer Ingelheim India Ltd, a wholly
owned subsidiary of Boerhringer Ingelheim (BI) to manufacture and market BI's products
in India.

In the year 2005, the company entered into a strategic alliance with Mallinckrodt
Pharmaceuticals Generics, a business unit of Tyco Healthcare to market the product
manufactured by the company under a joint label. In the same year, the company signed a
50:50 joint venture with Mayne Pharma of Australia to manufacture generic injectable,
cytotoxic (anti-cancer) medicines as well as active pharmacetical ingredients (API) for
global markets.

During the year 2005-06, the company signed a 50:50 joint venture with one of India's
top biotech companies Bharat Serums and Vaccines Ltd (BSV) and formed Zydus BSV
Pharma Pvt Ltd to develop, manufacture and market non-infringing and proprietary
Novel Drug Delivery System (NDDS) of an approved anti-cancer product for global
markets.

During the year 2006-07, the company entered into share purchase agreement to acquire
97.95% stake in Liva Healthcare Ltd, which is carrying on business of manufacturing and
marketing of Formulations. They established a green field facility for Solid Oral Dosage
Forms in Sikkim mainly for domestic market. They also installed Lyophilisation facility
at Moraiya plant with annual capacity of 7.5 million dosages to cater to both Indian and
International markets.

During the year 2007-08, the company restructured their formulation division namely
Alidac and launched two new sub division namely Corza and Fortiza. Also, they forayed
into the neutraceutical industry and launched a new division, Zydus Nutriva. The
upgradation of the injectibles facility at Moraiya was completed and also, they expanded
their manufacturing facility at Ankleshwar.

Zydus Healthcare Brasil Ltd, Brazil, a wholly owned subsidiary of the company acquired
100% shareholding of Quimica e Farmaceutica Nikkho Do Brasil Ltda, a Brazilian
Pharmaceutical company to expand their branded business in Brazil. Also, Zydus
Pharmaceuticals Inc, Japan, a wholly owned subsidiary of the company acquired 100%
shareholding in Nippon Universal Pharmaceuticals Co Ltd, Japanese Company, which is
carrying out business of manufacturing and marketing of pharmaceutical products in
Japan.

In February 2008, the company and Karo Bio of Sweden made a three year strategic
collaboration in the area of drug discovery and development. The company is in the
process of setting up a fine chemical facility at Dabhasa at a cost of about Rs 200 million,
which will commence their production in the financial year 2008-09.

In May 2008, the company entered into Spain with the acquisition of 100% stake in
Laboratories Combix. In June 2008, the company through their wholly owned subsidiary,
Zydus Healthcare SA Pty Ltd is acquiring majority state of 70% in Simayla
Pharmaceuticals of South Africa.

The company decided to demerge the Consumer Products Division of the company and
transferred to Carnation Nutra Analogue Foods Ltd, which is a subsidiary of Cadila
Healthcare and the merger of Zydus Hospital and Medical Research Pvt Ltd with the
company.

In August 2008, the company has entered into an agreement with WHO to explore a
possible collaboration in the development of a cocktail for the treatment of rabies,
through the use of monoclonal antibodies.

An Integrated Global Healthcare Company:

Zydus Cadila is an innovative global pharmaceutical company that discovers, develops,
manufactures and markets a broad range of healthcare products. The group’s operations
range from API to formulations, animal health products and cosmeceuticals.
Headquartered in the city of Ahmedabad in India, the group has global operations in four
continents spread across USA, Europe, Japan, Brazil, South Africa and 25 other emerging
markets.

In its mission to create healthier communities globally, Zydus Cadila delivers wide
ranging healthcare solutions and value to its customers. With over 11,000 employees
worldwide, a world-class research and development centre dedicated to discovery
research and eight state-of-the-art manufacturing plants, the group is dedicated to
improving people’s lives.

About US
A mission to create healthier communities
Zydus Cadila is dedicated to life…
In all its dimensions. Our world is shaped by a passion for innovation, commitment to partners and concern
for people in an effort to create healthier communities, globally.
A vision that unleashes value
To be a leading global healthcare provider with a robust product pipeline and sales of over $1 bn by 2010;
we shall achieve sales of over $3 bn by 2015 and be a research-based pharmaceutical company by 2020.

Formulation business in India:

With three multi-therapy divisions and eight specialty divisions, Zydus Cadila is one of the leading player in
the Indian healthcare industry. It is the leading player in the cardiovascular, gastrointestinal and women's
healthcare segments. The group has strong presence in respiratory, pain management, CNS, anti-infectives,
oncology, neurosciences, dermatology and nephrology segments. It has been able to maintain overall
position and market share through faster growing chronic / lifestyle segments. With several new product
introductions and pillar brands such as Aten, Ocid, Deriphyllin, Pantodac, Atorva, Nucoxia, Mifegest to name
a few, Zydus Cadila is considered a tour-de-force in therapy management and brand management. The
group has several in-licensing alliances with global multinationals such as Schering AG, Boehringer
Ingelheim, Viatris, etc.

TA-wise break-up of formulations revenue

The portfolio of over 200 products are marketed by a specialised field force of 3,000. With one of the
strongest distribution channels in the industry, the group reaches out to 1,00,000 chemists and serves
2,00,000 doctors including physicians, specialists and super specialists.

Consumer Products Business - Zydus Wellness Ltd.

Apart from a strong presence in the prescription market, the group also caters to the growing
health and wellness segment through its subsidiary Zydus Wellness Ltd.

Zydus Wellness aims to promote ‘healthy living’ by anticipating the emerging and day-to-day
needs in dietetic / health foods. Health and wellness have been identified as the emerging areas
in consumer healthcare. The Company is focussed on empowering individuals who wish to adopt
healthy eating habits and lifestyles.
The Company is a pioneer, offering healthier dietary options to the consumers. The product range
comprises Sugar Free Gold– India’s No.1 sweetener with a market share of over 70%, Sugar Free
Natura– a zero calorie sucralose based sugar substitute, Sugar Free D’lite– a low calorie healthy
drink and Nutralite– a premium cholesterol-free table spread. Nutralite has emerged as the
second largest brand in the category of butter and butter substitutes.

The Company also caters to the skincare segment with its Everyuth and Dermacare brands,
which occupy a unique distinction of being a ‘skincare brand from a healthcare company’.
Enriched with the power of natural ingredients, EverYuth has a strong presence in advanced
skincare segments like soap-free, face washes, face masks, scrubs etc.

Formulation business in Global:

Zydus Cadila has strong global opetations to market both formulations and APIs. With operations
in U.S.A., Europe, Latin America, Japan and over 40 emerging markets across the world, Zydus
Cadila is a global healthcare provider. The group also manufactures and markets a wide range of
intermediates and APIs.

Manufacturing:
A wide range of capabilities have helped the group create a robust manufacturing infrastructure. Spread
over five states of India, the group has eight state-of-the-art manufacturing facilities, creating a strong global
manufacturing hub for the group.

Proven strengths in formulations

manufacturing
Eight state-of-the-art plants
• Four formulation plants - one each at Moraiya in Ahmedabad, Goa, Baddi and Sikkim
• Two API plants at Ankleshwar and Dabhasa.
• An Agiolax plant in Goa
• An API plant in Mumbai to manufacture key intermediates of Pantoprazole

Intermediates and APIs

• Specialty chemicals, fine chemicals
• Advanced intermediates
• High end bulk actives
• Investigational bulk actives

Formulations

• Oral dosage forms (Tablets, hard and soft gel capsules)

• Injectables (Sterile liquids and lyophilised)
• Inhalers, transdermals, suppositories and vaccines
• Formulation development for ANDA candidates at a dedicated Pharmaceutical Technology Centre
• Development of specialised dosage forms

Key Factors:

• Zydus Cadila is a global healthcare provider and one of the top five pharma companies in India.

The company was founded by Late Mr. Ramanbhai B. Patel in 1952 and went on to become the second

largest pharma company in the early 1990’s.

• In 1995, the group restructured its operations and now operates as Cadila Healthcare Ltd., under

the aegis of the Zydus group. The company spearheaded by Mr. Pankaj R. Patel, Chairman and Managing

Director posted a turnover of over Rs. 3700 crores in 2009-10.

• The group has been listed as one of the ‘Best Under a Billion’ company from amongst 200

companies in Asia by Forbes.

• Proven expertise in manufacturing and marketing different dosage forms such as solid dosage

forms, injectables, metered dose inhalers, dry powder inhalers, transdermal patches, suppositories and

oncology formulations.

• Wide therapy coverage through three multi-therapy divisions and eleven speciality divisions. The

divisions are spearheaded by some of the stalwarts in the field of pharma marketing.
• A dedicated field force of 3300 reaches out to super specialists, specialists, surgeons, physicians

and the rural markets.

• The group has a strong presence in the cardiovascular, gastrointestinal, women’s healthcare

segments, respiratory, pain management, CNS, anti-infectives, oncology, neurosciences, dermatology and

nephrology segments.

• Leading the way through new product introductions, the group was the first to launch Nucoxia

(Etoricoxib), Nupatch (Diclofenac Patch), Pantodac (Pantoprazole), Mifegest (Mifepristone), Penegra

(Sildenafil Citrate), Providac Techsules, Betaferon, Fludara, Slimona (Rimonabant) and Novolizer in India.

• The group has several brands that feature amongst the top 300 pharmaceutical brands in India.

• The group has a globally compliant manufacturing infrastructure comprising eight state-of-the-art

facilities which support product launches not just in India but also in the regulated markets of U.S., Europe

and Latin America.

• Three of the group’s facilities including the formulation manufacturing plant at Moraiya, and API

plants at Ankleshwar and Dabhasa near Vadodara are approved by the USFDA.

• More than 900 professionals spearhead the group’s research programme.

• Over 350 scientists are working on new molecular entity research at the Zydus Research Centre.

The group has eight INDs in various stages of clinical trials.

• Zydus Cadila is a partner of choice for several global pharma majors such as Boehringer

Ingelheim, Bayer Schering Pharma, Madaus AG, Nycomed, Hospira, Bio Sidus of Argentina, Mallinckrodt

of USA, Abbott to name a few.

• One of the most reputed pharma companies globally, Zydus Cadila aims to be a leading global

healthcare provider with a robust product pipeline and sales of over $1 billion by 2010. It plans to achieve

sales of over $3 billion by 2015 and be a global research-driven company by 2020.

Core value:
In the community:

In keeping with its mission to create healthier communities globally, Zydus Cadila is actively
involved in developing the community of which it forms a part.

Through the Ramanbhai Foundation, it has undertaken initiatives in the field of pharmaceutical
research, education and healthcare. Under the aegis of the Foundation, the group organises an
International Symposium on the latest trends in Pharmaceutical Sciences, once every two years.
Three International symposia have been held so far with more than 40 research scientists,
academicians and research professionals from across the world sharing their insights on the
latest developments in pharmaceutical research.

‘The Zydus School for Excellence’ – a centre for learning where young minds are free to grow in
relationship to his or her potential has also been set up under the aegis of the Foundation. The
‘Shri Ramanbhai Patel Memorial Scholarship Programme’ jointly funded by a grant from the
Ramanbhai Foundation and Zydus School for Excellence funds the education of students from
disadvantaged backgrounds.

Shri Ramanbhai B. Patel - AMA Centre for Excellence in Education, provides a platform for
parents, teachers and students to highlight the critical educational issues of the day. The centre
conducts open house discussions, memorial lectures on excellence in education, progressive
learning programmes for academicians and knowledge sharing forums. The centre also honours
teachers for their contributions to a child’s world of learning.

Dedicated to the memory of the group’s founder, the IPA – Shri Ramanbhai B. Patel Foundation
(IRF) has been jointly set up with the Indian Pharmaceutical Association. IRF recognises and
honours ‘commitment and excellence’ in the field of pharmacy.

As a part of its outreach programmes, the group organises rural healthcare camps annually with
its team of medical advisors and employees, volunteering their services. So far, the group has
organised general healthcare camps, diagnostic, dental-care, eye-care and paediatric camps.
The group has also initiated 'Project Unnati' for adolescent girls at Moraiya which focusses on
health and overall development.

Through the Ramanbhai Foundation, the group also extends its support during times of natural
calamities.

In recognition of its CSR initiatives, the group bagged the ‘Social and Corporate Governance
Awards 2008’ in the ‘Best Social Responsibility Practice’ category presented by the BSE,
NASSCOM Foundation and Times Foundation

Research Focus:
At Zydus Research Centre (ZRC), our focus is on finding innovative therapies for diseases affecting
mankind through continuous research and development. The major areas of research includes:

• New Molecular Entities

• Novel Drug Delivery Systems
• Therapeutic proteins and Vaccine by r-DNA technology
• Identification and validation of Therapeutic Targets

Scientific Advisory Board:

ZRC has constituted a Scientific Advisory Board comprising of world renowned scientists and clinicians to
advice the group in its research endeavors.

Dr. Richard DiMarchi

Dr. DiMarchi is presently a Professor of Chemistry and the Jack and Linda Gill Distinguished Chair in
Biomolecular Science at Indiana University. He currently serves as a co-founder and Board Chairman of
Ambrx Inc. Dr. DiMarchi was formerly Group Vice-President for Biotechnology and Product Development at
Lilly Research Laboratories, where he made major contributions to Lilly in biotechnology and endocrinology.
Dr. DiMarchi was directly involved in the discovery and development of several Lilly drugs, including
Humulin(R), Humatrope(R), Evista(R), Xigris(R), and Forteo(R). He was a co-inventor of Humalog(R), the
first biosynthetic protein approved for human use. ( For more details,click here)
Dr. John Amatruda
Most recently Dr. Amatruda was Senior Vice President and Franchise Head for Diabetes and Obesity and a
member of the Research Management Committee at Merck. Dr Amatruda graduated from Yale University,
received his MD degree from the Medical College of Wisconsin and did his internship and residency in
Internal Medicine and Fellowship in Endocrinology and Metabolism at The Johns Hopkins Hospital. He is
board certified in internal medicine and Endocrinology and Metabolism. ( For more details,click here)

Suad Efendic, MD, PhD, Professor

Suad Efendic is a Professor of Endocrinology at Karolinska Institutet, Adjunct Professor of Physiology at the
University of Toronto, and Professor of Medicine at the University of Zagreb. Since 1991 he has been a
member of the Nobel prize Assembly. From 1988-1995 he was the Head of the Department of
Endocrinology and Diabetology at Karolinska Hospital. ( For more details,click here)

Dr. Lee S. Simon

Dr. Simon is currently an Associate Clinical Professor of Medicine at Harvard Medical School and Beth
Israel Deaconess Medical Center (BIDMC) in Boston, MA, USA. Previously, he was Director of
Rheumatology Clinical Research, an Associate Chief of Medicine, and Director of Graduate Medical
Education at BIDMC. ( For more details,click here)

Dr. Robert R. Henry

Dr. Henry is an internationally renowned clinical investigator and scientist. Dr. Henry is Professor of
Medicine at the University of California San Diego and the Chief of Endocrinology at the VA San Diego
Healthcare System. ( For more details,click here)

Dr. Charles F. Burant, MD, PhD

Dr. Charles F. Burant, MD, PhD is Professor of Internal Medicine at the University of Michigan Health
System in Ann Arbor, Michigan. He currently is the Robert C. and Veronica Atkins Professor of Metabolism
and directs the Michigan Metabolomics and Obesity Center. His research interests are in the areas of the
molecular and cellular biology of insulin resistance and the effect of insulin resistance on ß-cell function as
well as lipid and glucose metabolism. His clinical interests are focused on type 2 diabetes, insulin resistance,
and the metabolic syndrome. Dr Burant is an Associate Editor for the American Journal of Physiology-
Endocrinology and Metabolism. He is active in the American Diabetes Association, serving on the Research
Policy Committee and the Board of Directors of the Research Foundation.
( For more details,click here)

In addition to the Scientific Advisory Board, ZRC also has well-experienced advisors to help the
research team in making appropriate decisions on various targets and research areas of focus to the
company.

Dr. Walter Wahli

Dr. Walter Wahli received his PhD in Bern in 1977. He carried out a post-doctoral fellowship with Dr. Igor
Dawid at the Department of Embryology, Carnegie Institution of Washington in Baltimore. He then was at
the Department of Biochemistry of the National Cancer Institute, NIH, in Bethesda, as visiting fellow and
visiting associate. He moved to Lausanne in 1980, where he was appointed Professor of biology and
Director of the Institute of animal biology of the University. He was Vice-Director for Research and
Postgraduate Education of the University between 1999 and 2003. In 2003, he became Director of the
Center for Integrative Genomics and in 2004 he was elected President of the Biology and Medicine Division
of the Swiss National Science Foundation.

The Otto Naegeli Award 2002 and the European Lipid Science Award 2002 have honored the work of Dr.
Walter Wahli who has discovered novel nuclear hormone receptors, has identified specific ligands for these
receptors, and has demonstrated the central physiological significance of these regulatory proteins in
metabolism, inflammation, and wound healing. Dr. Wahli has published many publications in well respected
and peer viewed journals and earned a respectable position in exploring mechanism of different diseases
related to nuclear receptors.

About ZRC:

Zydus Research Centre (ZRC) is the dedicated research and development arm of Zydus
Cadila, established in the year 2000. This state-of-the-art research centre, spread over an
area of 3,60,000 sq.ft., is located at Ahmedabad, in the western part of India. A team of
over 300 research scientists are actively engaged in research in various disciplines of
Medicinal Chemistry, Biotechnology, Cell Biology, Bioinformatics, Genomics,
Molecular Biology, Pharmacology, Toxicology, Microbiology, Analytical Research,
Clinical Research, Novel Process Research and Novel Drug Delivery Research.

Research Areas:
Zydus Research Centre (ZRC) is the dedicated research and development arm of Zydus Cadila, established
in the year 2000.

At ZRC, research is mainly focussed on

NME research

• Metabolic Disorders
• Diabetes
• Obesity
• Dyslipidemia
• Inflammation and Pain
• Rheumatoid arthritis
• Pain
• Bacterial Infections

Biotechnology Research

• Development of Biogeneric therapeutic proteins

• Development of Antibodies
• Development of Vaccines
• Search for Novel Targets
• Validation of Targets

Chemical Manufacturing and Control

Development of Novel processes for NME's from Medicinal Chemistry
department

• Chiral synthesis of drug and drug intermediates

• Resolution of racemates
• Studies in polymorphism of drug candidates
• Development of novel process of peptide drugs

Novel Drug Delivery Research

• Research in delivery of proteins and peptides

• Delivery of NME

R&D Organisation:
The R & D Organisation has capabilities to conduct Drug Discovery and Development from
concept to IND enabling pre-clinical and clinical development.

Scientific Activities:
The Ramanbhai Foundation International Symposium is a biannual series of
symposia devoted to the discussion of new trends in the pharmaceutical industry with
a view to promoting scientific excellence in drug discovery and development.

Ramanbhai Foundation is named after a pathfinder, Late Mr. Ramanbhai B. Patel,

who had dedicated his life to the quest of knowledge, as an academician,
entrepreneur and a research scientist. He believed that new paths would surely open
up if one has the creative will to discover it. (To know more about Mr. Ramanbhai B.
Patel, Click here)
The theme of the RBF
1st International
Symposium held in
the year 2003 was
'Current Trends in
Pharmaceutical
Sciences'. The
emphasis was on the
development of
therapeutic molecules
from mouse to man.

The theme of the

Ramanbhai
Foundation 2nd
International
Symposium was
'Current Trends in
Pharmaceutical
 Sciences' with an
emphasis on the role
of genomics and
proteomics research
in drug discovery and
development process.
The symposium was held at ZRC from January 23-25, 2005.

The Ramanbhai Foundation 3rd International Symposium focused on “Current Trends in

Pharmaceutical Sciences: Advances in diabetes therapy - Basic Science and Clinical Aspects”.
The symposium was held at Zydus Research Centre, Ahmedabad from February 1-3, 2007.

The Ramanbhai Foundation 4th International Symposium was focussed on “Advances in

Cardiometabolic Research” and held from February 2-5, 2009, with focus on research in the area
of cardiovascular and metabolic diseases such as atherosclerosis, hypertension, heart failure,
diabetes and obesity.

To learn more about this biannual event and participate, please visit www.rbfsymposium.net

Discovery Pipeline:

New Molecular Entities in Development

Biological Testing

Several NME's are under biological testing for treatment of arthritis, obesity and cardiovascular diseases.
Department of Biotechnology

• Cloning, Fermentation and Purification of Therapeutic Proteins and Vaccines

• Development of Animal Feed Supplement

• Development of Diagnostic Kits

Patents

ZRC has filed over 108 patents in various therapeutic areas of NME research, Process Research, Novel
Process Research, Novel Drug Delivery and Biologicals, since its inception. Several of them have already
been granted US patents

Publications:
ZRC encourages scientists to publish their research findings in leading national and international journals.
Some of the publications from
ZRC are listed below :

Bioisosteric replacement of Dihydropyrazole of 4S-(-)-3-(4-chlorophenyl)-N-methyl-N’-[(4-chlorophenyl)-

sulfonyl]-4-phenyl-4, 5-dihydro-1H-pyrazole-1-caboxamidine (SLV-319) a potent CB1 receptor antagonist by
Imidazole and Oxazole.
Bioorg. Med. Chem. Lett. 2008, 18, 963

• Convenient Synthesis of Structurally Novel 1,3-Disubstituted Azetidine Derivatives Synthetic

Communications, 2008, (accepted)

• Synthesis and antidiabetic activity of 2,5-disubstituted-3-imidazol-2-yl-pyrrolo[2,3-b]pyridines and thieno

[2,3-b]pyridines
Bioorganic and Medicinal Chemistry, 2007, 15 (21) , 6782-6795.

• An improved synthesis of Fmoc-N-methyl serine and threonine

Tetrahedron Letters, 2007, 48 (29), 5003-5005

• Synthesis and antidiabetic activity of 3,6,7-trisubstituted-2-(1H-imidazol- 2-ylsulfanyl)quinoxalines and

quinoxalin-2-yl isothioureas (2007)
Archiv der Pharmazie, 340 (7), pp. 359-366

• Synthesis of 3,8,9-trisubstituted-1,7,9-triaza-fluorene-6-carboxylic acid derivatives as a new class of insulin

secretagogues
Bioorganic and Medicinal Chemistry, 2007, 15 (17), 5950-5964

• Design, Synthesis and biological evaluation of substituted N-(thieno[2,3-b]pyridin 3-yl)-guanidines, N-(1H-

pyrrolo [2,3-b]pyridin-3-yl)-guanidines and N-(1H-indol-3yl)-guanidines.
Bioorganic and Medicinal Chemistry,2007, 15, 3248-65

• Diaryl Dihydro pyrazole 3-carboxamides with significant in vivo antiobesity activity related to CB1
antagonisum: synthesis,Biological evaluation,and molecular modeling in the homology model.
Journal of Medicinal Chemistry, 2007, 50, 5951-5966

• Synthesis and in vitro antibacterial activities of novel oxazolidinones Eur. J. Med. Chem. 2007, In Press,
Corrected Proof, Available online 27 May 2007 (doi:10.1016/j.ejmech.2007.05.003).

• Synthesis and anti-bacterial activity of 4,5,6,7-tetrahydro-thieno[3,2-c] pyridine quinolones.

Bioorganic and Medicinal Chemistry Letters, 2007, 17, 1924-1929

• 3D QSAR studies of N-4-arylacryloylpiperazin-1-yl-phenyl-oxazolidinones: A novel class of antibacterial

agents.
Bioorg. Med. Chem. Lett. 2006, 16, 3817
• Novel Anti-infective Compounds
Pure Appl. Chem. 2005, 77, 195.

• Novel 4-N-substituted aryl pent-2-ene-1,4-dione derivatives of piperazinyloxazolidinones as anti-bacterials.

Bioorg. Med. Chem. Lett., 2006, 16: 1557-1561

• Direct injection, column switching–liquid chromatographic technique for the estimation of rabeprazole in
bioequivalence study
Journal of Chromatography B, 2004, 813, 247–254.

• Novel tetrahydro-thieno pyridyl oxazolidinone: an anti-bacterial agent

Bioorganic & Medicinal Chemistry, 2004, 12, 4557-4564.

• Novel Mannich ketones of oxazolidinones as anti-bacterial agents

European Journal of Medicinal Chemistry, 2004, 39, 989–992.

• Oxazolidinone: Search for highly potent antibacterial

Bioorganic & Medicinal Chemistry Letters, 2004, 14, 3139-3142.

• Contributory patent infringement and the pharmaceutical industry

Journal of Intellectual Property Rights, 2003, 8, 302-311.

Collaborations:
Zydus Cadila is constantly seeking newer opportunities in:

• Collaborative research and development

• In-licensing of technologies / NME's
• Out-licensing / co-development of Zydus's drug candidates

For further details, please contact or submit your opportunities to:

Business Development
Zydus Research Centre
Sarkhej-Bavla N.H. No. 8A
Moraiya, Ahmedabad - 382210
Gujarat, India
Ph: +91-2717-250801
Fax: +91-2717-250606
Email: zrc@zyduscadila.com

Investor:
It is our endeavour to provide the latest information for the benefit of the investing community. This section
also provides for downloading of various forms such as those for requesting change in address, transfer of
shares and for issuance of share certificates.

We welcome your suggestions and comments about the various features and facilities provided in this
section. We would also like to know from you other features or facilities that you would like us to provide in
this section.
Shareholding pattern for the quarter ended on 30th June, 2010

(I)(a) Statement showing Shareholding Pattern

Cate Category of Number Total Number of Total Shareholding Shares pledged or

- shareholder of number of shares held as a percentage of otherwise encumbered
gory share- shares in de total number of
Cod holders materialized shares
e form
As a As a No. of As a
percenta Percent- shares percentage
ge of tage of
(II) (IV) (V) (A+B) (A+B+C) (IX) = (VIII)/
(I) (III) (VII) (IV)*100
(VI) (VIII)

(A) Shareholding of
Promoter and
Promoter Group

(1) Indian

(a) Individuals / Hindu 10 153134446 153134446 74.79 74.79

Undivided Family
(incl. a Family
Trust)

(b) Central Nil - - - -

Government /
State
Government(s)

(c) Bodies Corporate 1 3600 3600 - -

(d) Financial Nil - - - -

Institutions /
Banks

(e) Any Other Nil - - - -

(Specify)

(Sub-Total (A)(1) 11 153138046 153138046 74.79 74.79 Nil

(2) Foreign

(a) Individuals (Non- Nil - - - -

Resident
Individuals /
Foreign
 Individuals)

(b) Bodies Corporate Nil - - - -

(c) Institutions Nil - - - -

(d) Any Other Nil - - - -

(specify)

(Sub-Total (A)(2) Nil - - - - Nil -

Total 11 153138046 153138046 74.79 74.79 Nil -

Shareholding of
Promoter and
Promoter Group
(A) = (A)(1)+(A)
(2)

(B) Public N.A. N.A.

Shareholding

(1) Institutions N.A. N.A.

(a) Mutual Funds / 65 14265900 14262366 6.97 6.97

UTI

(b) Financial 14 6476 4799 0 0

Institutions /
Banks

(c) Central Nil - - - -

Government /
State
Government(s)

(d) Venture Capital Nil - - - -

Funds

(e) Insurance 10 12568878 12568878 6.14 6.14

Companies

(f) Foreign 62 9095389 9095014 4.44 4.44

Institutional
Investors

(g) Foreign Venture Nil - - - -

Capital Investors

(h) Any Other Nil - - - -

(Specify)
 Sub-Total (B)(1) 151 35936643 35931057 17.55 17.55

(2) Non-Institutions

(a) Bodies Corporate 702 2266849 2261923 1.11 1.11

(b) Individuals -

1. Individual 37846 *9060146 7301612 4.42 4.42

Shareholde
rs holding
nominal
share
capital up
to Rs.114 1545484 1491604 0.76 0.76
lakh.

2. Individual
shareholde
rs holding
nominal
share
capital in
excess of
Rs.1 lakh.

(c) Any Other 606 2801352 2781780 1.37 1.37 N.A. N.A.
(specify) NRI/OCB

Sub-Total (B)(2) 39168 15673831 13836919 7.66 7.66 N.A. N.A.

Total Public 39319 51610474 49767976 25.21 25.21 N.A. N.A.

shareholding
(B) = (B)(1)+(B)
(2)

TOTAL (A)+(B) 39330 204748520 202906022 100.00 100.00

(C) Shares held by Nil - - - - N.A. N.A.

Custodians and
against which
Depository
Receipts have
been issued
GRAND TOTAL
(A)+(B)+(C)

GRAND 39330 204748520 202906022 100.00 100.00 N.A. N.A.

TOTAL(A)+(B)+
 (C)

* Including 29453 shares in transit.

(I)(b) Statement showing Shareholding of persons belonging to the category "Promoter

and Promoter Group"

Sr. Name of the Total shares held Shares pledged or otherwise encumbered
No. Shareholder
Number of Shares as a Number As a percent- As a % of
Shares percentage of tage grand total (A)+
total number of (B)+(C) of sub-
shares {i.e., clause (I)(a)
Grand Total
(A)+(B)+(C)
indicated in
Statement at
(III) Para (I)(a) (V)
(I)
above} (VI)= (V)/ (VII)
(II)
(IV) (III)*100

1. ZYDUS FAMILY 153107446 74.78 Nil N.A. -

TRUST

2. PRIPAN 3600 0.002 Nil N.A. -

INVESTMENT
PVT. LTD.

3. SHIVANI 3000 0.002 Nil N.A. -

PANKAJBHAI
PATEL JTLY.
PANKAJBHAI
RAMANBHAI
PATEL

4. PANKAJBHAI 3000 0.002 Nil N.A. -

RAMANBHAI PTEL
JTLY.
PRITIBEN
PANKAJBHAI
PATEL

5. PANKAJBHAI 3000 0.002 Nil N.A. -

RAMANBHAI
PATEL (HUF)
6. PRITIBEN 3000 0.002 Nil N.A. -
PANKAJBHAI
PATEL JTLY.
PANKAJBHAI
RAMANBHAI
PATEL

7. TARABEN 3000 0.002 Nil N.A. -

RAMANBHAI
PATEL JTLY.
PANKAJBHAI
RAMANBHAI
PATEL

8. RAMANBHAI B. 3000 0.002 Nil N.A. -

PATEL (HUF)

9. PANKAJBHAI 3000 0.002 Nil N.A. -

RAMANBHAI
PATEL JTLY.
PRITIBEN
PANKAJBHAI
PATEL
(R. B. PATEL WILL
PANKAJ TRUST)

10. PANKAJBHAI 3000 0.002 Nil N.A. -

RAMANBHAI
PATEL JTLY.
SHARVIL
PANKAJBHAI
PATEL
(P. R. PATEL
SMALLER HUF)

11. SHARVIL 3000 0.002 Nil N.A. -

PANKAJBHAI
PATEL

TOTAL 153138046 74.79 Nil N.A. -

(I)(c) Statement showing Shareholding of persons belonging to the category "Public"

and holding more than 1% of the total number of shares

Sr. Name of the Shareholder Number of Shares as a percentage of total number

No. Shares of shares {i.e., Grand Total (A)+(B)+(C)
 indicated in Statement at Para (I)(a)
above}

1. LIFE INSURANCE COPRORATION OF 8085210 3.95

INDIA

2. DALI LIMITED 2512327 1.23

TOTAL 10597537 5.18

(I)(d) Statement showing details of locked-in shares Not Applicable

Sr. Name of the Shareholder Number of Locked-in shares as a percentage of

No. locked-in total number of shares {i.e., Grand Total
Shares (A)+(B)+(C) indicated in Statement at
Para (I)(a) above}

1. Zydus Family Trust (Promoter Group)@ 25221326 12.32

TOTAL 25221326 12.32

@ Lock-in till 05.03.2012

(II)(a) Statement showing details of Depository Receipts (DRs) Not Applicable

Sr. Type of outstanding DR Number of outstanding Number of shares Shares underlying

No. (ADRs, GDRs, SDRs, DRs underlying outstanding DRs as a
etc.) outstanding DRs percentage of total number
of shares {i.e., Grand Total
(A)+(B)+(C) indicated in
Statement at Para (I)(a)
above}

TOTAL Nil - -

(II)(b) Statement showing Holding of Depository Receipts (DRs), where underlying

shares are in excess of 1% of the total number of shares. Not applicable

Sr. Name of the DR Holder Type of outstanding DR Number of shares Shares underlying
No. (ADRs, GDRs, SDRs, underlying outstanding DRs as a
etc.) outstanding DRs percentage of total number
of shares {i.e., Grand Total
(A)+(B)+(C) indicated in
 Statement at Para (I)(a)
above}

TOTAL Nil -